Table I.
Clinicopathological characteristics of patients who received metronomic regimens and those who received other regimens.
| Characteristics | All patients | Patients receiving METb | Patients not receiving MET | P-value |
|---|---|---|---|---|
| Patient no. | 80 | 52 | 28 | |
| Age, years | 59 (32–82) | 60 (40–81) | 51 (32–82) | 0.0013 |
| Tumor grade | 2 (1–3) | 2 (1–3) | 3 (1–3) | 0.025 |
| DFI, months | 37 (3–24) | 42 (10–241) | 37 (3–128) | 0.201 |
| Disease sites, n | 2 (1–6) | 2 (1–6) | 2 (1–6) | 0.869 |
| Visceral lesions, % | 56.2 | 53.8 | 57.7 | 0.75 |
| AT pretreatment, % | 40.7 | 39.2 | 42.3 | 0.872 |
| Hormone-sensitive tumors, % | 59 | 63.5 | 50 | 0.258 |
| HER2-overexpressing tumors, % | 21.9 | 23.4 | 19.3 | 0.743 |
| Triple-negative tumors, % | 30.8 | 25 | 42.3 | 0.121 |
| Chemotherapy cycles for BC, n | 4 (1–7) | 4 (1–7) | 3 (1–5) | 0.034 |
| Chemotherapy cycles for MBC, n | 3 (1–7) | 3 (1–7) | 2 (1–4) | 0.0018 |
Values are presented as median (range). Bold print indicates statistical significance. MET, metronomic regimen; DFI, disease-free interval; AT, anthracyclines and taxanes; HER2, human epidermal growth factor receptor 2; BC, breast cancer; MBC, metastatic breast cancer.